传恒瑞医药IPO将以44.05元上限定价

老虎资讯综合05-21

据IFR引述消息人士报道，中国创新型制药企业恒瑞医药IPO将以44.05元上限定价，集资98.9亿元。

此前有传，恒瑞医药因新股认购需求强劲，将提前一日于周一(19日)下午5时结束接受机构投资者认购。据悉，机构投资者的认购需求已超过整个招股规模。

恒瑞医药拟全球发售2.25亿股，香港公开发售占1,234.86万股，国际发售占2.12亿股。每股招股价介乎41.45至44.05元，集资最多98.9亿元，净集资约94.58亿元。每手200股计，一手入场费8,898.85元。该股预期周五(23日)挂牌，联席保荐人为摩根士丹利、花旗及华泰国际。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

吉伊卡哇
05-21
吉伊卡哇
意料之中，正常逻辑。好股上新实在太火了，宁王基本都没折价。

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1184516020?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","is_english":false,"pubTime":"2025-05-21 11:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184516020","market":"us","top_or_hot":-1,"title":"传恒瑞医药IPO将以44.05元上限定价","media":"老虎资讯综合","content":"<html><head></head><body><p>据IFR引述消息人士报道，中国创新型制药企业恒瑞医药IPO将以44.05元上限定价，集资98.9亿元。</p><p style=\"text-align: justify;\">此前有传，恒瑞医药因新股认购需求强劲，将提前一日于周一(19日)下午5时结束接受机构投资者认购。据悉，机构投资者的认购需求已超过整个招股规模。</p><p style=\"text-align: justify;\">恒瑞医药拟全球发售2.25亿股，香港公开发售占1,234.86万股，国际发售占2.12亿股。每股招股价介乎41.45至44.05元，集资最多98.9亿元，净集资约94.58亿元。每手200股计，一手入场费8,898.85元。该股预期周五(23日)挂牌，联席保荐人为摩根士丹利、花旗及华泰国际。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>传恒瑞医药IPO将以44.05元上限定价</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n传恒瑞医药IPO将以44.05元上限定价\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2025-05-21 11:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>据IFR引述消息人士报道，中国创新型制药企业恒瑞医药IPO将以44.05元上限定价，集资98.9亿元。</p><p style=\"text-align: justify;\">此前有传，恒瑞医药因新股认购需求强劲，将提前一日于周一(19日)下午5时结束接受机构投资者认购。据悉，机构投资者的认购需求已超过整个招股规模。</p><p style=\"text-align: justify;\">恒瑞医药拟全球发售2.25亿股，香港公开发售占1,234.86万股，国际发售占2.12亿股。每股招股价介乎41.45至44.05元，集资最多98.9亿元，净集资约94.58亿元。每手200股计，一手入场费8,898.85元。该股预期周五(23日)挂牌，联席保荐人为摩根士丹利、花旗及华泰国际。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1184516020","we_media_id":"102","thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184516020","pubTimestamp":1747797008,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"老虎资讯综合","introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"据IFR引述消息人士报道，中国创新型制药企业恒瑞医药(01276.HK)IPO将以44.05元上限定价，集资98.9亿元。此前有传，恒瑞医药因新股认购需求强劲，将提前一日于周一(19日)下午5时结束接受机构投资者认购。据悉，机构投资者的认购需求已超过整个招股规模。恒瑞医药拟全球发售2.25亿股，香港公开发售占1,234.86万股，国际发售占2.12亿股。每股招股价介乎41.45至44.05元，集资最多98.9亿元，净集资约94.58亿元。每手200股计，一手入场费8,898.85元。该股预期周五(23日)挂牌，联席保荐人为摩根士丹利、花旗及华泰国际。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{},"translate_title":"It is rumored that Hengrui Medicine's IPO will be priced at an upper limit of 44.05 yuan","themeId":"00417d1c9fabb8d35421e92b7c290bbb","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/579af6e77d94ba92cfef17c86ca750aa","symbols_score_info":{"01276":1.1},"content_text":"据IFR引述消息人士报道，中国创新型制药企业恒瑞医药IPO将以44.05元上限定价，集资98.9亿元。此前有传，恒瑞医药因新股认购需求强劲，将提前一日于周一(19日)下午5时结束接受机构投资者认购。据悉，机构投资者的认购需求已超过整个招股规模。恒瑞医药拟全球发售2.25亿股，香港公开发售占1,234.86万股，国际发售占2.12亿股。每股招股价介乎41.45至44.05元，集资最多98.9亿元，净集资约94.58亿元。每手200股计，一手入场费8,898.85元。该股预期周五(23日)挂牌，联席保荐人为摩根士丹利、花旗及华泰国际。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[{"id":437400486744216,"gmtCreate":1747799868909,"gmtModify":1747799870801,"author":{"id":"3437436807230030","authorId":"3437436807230030","name":"吉伊卡哇","avatar":"https://static.tigerbbs.com/bd93c5424780467f7526a7fe2e938782","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"3437436807230030","authorIdStr":"3437436807230030"},"htmlText":"意料之中，正常逻辑。好股上新实在太火了，宁王基本都没折价。","listText":"意料之中，正常逻辑。好股上新实在太火了，宁王基本都没折价。","text":"意料之中，正常逻辑。好股上新实在太火了，宁王基本都没折价。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/437400486744216","repostId":1184516020,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":1,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.1","shortVersion":"4.34.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184516020"}